Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT05496998

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05496998
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05496998. Allocation not applicable; no masking; primary purpose treatment. Start 2023-02-07 (actual); primary completion 2029-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Acronym
APOLLO-EU
Condition
Mitral Regurgitation
Intervention (Device)
Medtronic Intrepid™ TMVR TF System
Lead sponsor
Medtronic Cardiovascular (class: industry)

Record details

Record id
cardio:ct-nct05496998
Content hash
531662b66cb2cbc9e83d0d89b47b9a937e5d5bda14feb053cccd90964d4fead1